Market Views – Page 27 – media

Japan’s PeptiDream Bags $1.11B+ R&D Pact With Bayer

Peptidream Inc. has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
- Source: Biospace
- 513
- November 21, 2017
Market Views PDC PDPS peptide-based
High-tech neuroprosthetic ‘Luke’ arm lets amputee touch and feel again

Walgamott was describing the results of an experimental surgery to The Washington Post, where a prosthetic known as the “Luke” arm had been attached with electrodes implanted into his nerves. The real estate agent had lost his hand and most of his arm in an electrical accident 14 years ago, and he volunteered for the program at the University of Utah.
- Source: digitaltrends
- 410
- November 20, 2017
Market Views neuroprosthetic prosthetic
This Artificial Kidney Eliminates The Need For Kidney Dialysis

It is estimated by The National Kidney Foundation that over 100,000 patients are on the waiting list for kidney donors. A further 3,000 names are added to the list every year. An average patient has to wait for 3.6 years for a viable transplant. The patients are treated with dialysis while they are waiting for a transplant and only one in three patients survive for more than five years without a transplant. All that could change as scientists have developed the world’s first artificial kidney.
- Source: wonderfulengineering
- 484
- November 20, 2017
artificial kidney Market Views
Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck

Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada.
- Source: biotech-365
- 539
- November 20, 2017
autoimmune immunotherapy Market Views
Clinical trial shows treatment is ‘transformative’ for babies with spinal muscular atrophy

Infants with the most severe form of spinal muscular atrophy (SMA) were more likely to show gains in motor function and were 47 percent more likely to survive without permanent assisted ventilation support when treated with a new medication, according to a study published today in the New England Journal of Medicine. The drug, nusinersen, performed so well that the study was stopped early and the treatment was approved shortly thereafter by the U.S. Food and Drug Administration (FDA) for all patients with this progressive neuromuscular disorder.
- Source: sciencedaily
- 462
- November 17, 2017
Market Views neuromuscular disorder SMA
Medical first-Doctors attempt to gene-edit a living patient’s DNA

A man may soon be forever free of the previously incurable disease he was born with 44 years ago. On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
- Source: flipboard
- 436
- November 16, 2017
enzyme Hunter syndrome Market Views mucopolysaccharides
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 852
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
Eight cases of tuberculosis confirmed at Hong Kong secondary school

The Hong Kong health authorities have confirmed that eight people from a secondary school in Sha Tin were infected with tuberculosis.
- Source: scmp
- 542
- November 15, 2017
Market Views tuberculosis
AstraZeneca-FASENRA Gets US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca and its global biologics research and development arm, MedImmune, said Tuesay that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Source: businessinsider
- 574
- November 15, 2017
asthma eosinophilic Market Views New Approvals
New tool developed to study stem cell transplants as a potential way to treat HIV

A decade ago, the medical world was shocked when a patient in Berlin, Germany, had been declared free of HIV after receiving a stem cell transplant to treat cancer. Doctors have repeatedly tried to replicate the result, but this HIV cure has evaded other patients so far.
- Source: sciencedaily
- 504
- November 14, 2017
HIV Market Views stem cells

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.